LB Pharmaceuticals

US · LBRX #3180 by market cap Listed 2025

34.16 -0.10 -0.29%

Live - 5344 symbols - heartbeat 194s ago · 2026-10-08 09:09

Pre-market 33.48 -1.99%

After-hours 34.16 0.00%

Market cap: 1.10B
P/E (TTM): -11.43
P/B: 3.32
EPS: -1.00
Div yield: 0.00%
52W pos: 55%

Reader sentiment Are you bullish or bearish on LBRX?

Anonymous reader poll. Unscientific, not investment advice.

About LB Pharmaceuticals

LB Pharmaceuticals, Inc. engages in the research and development of novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its product pipeline includes LB-102, is a Phase 3-ready oral, small molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms, characterized by hallucinations, delusions, and other positive symptoms. The company was founded by Vince Grattan and Zachary Prensky in 2015 and is headquartered in New York.

Founded: 2015
CEO: Ms. Heather Turner
Employees: 27
Headquarters: New York, New York, United States of America
Fiscal year end: 12-31
Website: lbpharma.us

Company profile

Exchange: US
Symbol: LBRX
Market-cap rank: #3180
Listing date: 2025-09-11
Market cap: 1.10B
Float cap: 903.89M
Shares out: 32.26M
Float shares: 26.46M

Sectors & themes

Biotechnology

Browse all sectors & themes

Quote time 2026-10-08 09:09:08 · For reference only, not investment advice and not tailored to your situation.